

MEDIA RELEASE

Board and Management Changes

Sydney, Australia 28 September 2020 – Azure Health Technology Limited (AZT) advises that Mr Gregory Starr has resigned as a Director of the Company, and as a member of the Audit Committee and the Remuneration Committee.

The Board wishes to thank Mr Starr for his significant contribution to the Company as a Director and as a member of various committees.

Mr Andrew Bristow has been appointed as a member of the Audit Committee and the Remuneration Committee.

Together with the above changes AZT advises that Mr Aiden Wei Jiang and Mr Kevin Chen have resigned as directors and the Board thanks them for their contributions.

Management Changes

Mr Ian Forbes has been appointed as Chief Financial Officer and Ms Catriona Glover has been appointed as Company Secretary.

For more information please contact:

Dr Glenn Tong
CEO and Managing Director
Tel: +61 (0) 412 193 350

Mr Warrick Lace
Investor Relations
Reach Corporate Pty Ltd
+61 (0) 404 656 408

About Azure Health Technology Limited

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.aztht.com.au
